![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 1.83% | 27.75 | 27.50 | 28.00 | 27.75 | 27.25 | 27.25 | 1,058,943 | 14:49:29 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.65 | 185.4M |
TIDMVENN
RNS Number : 4096Y
Venn Life Sciences Holdings PLC
03 March 2017
3 March 2017
Venn Life Sciences Holdings Plc
("Venn Life Sciences" or the "Company")
Year End Update
Venn Life Sciences (AIM: VENN), a growing Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations, today provides the following update.
2016 represented another year of strong growth for Venn with sales in excess of EUR18m (2015 EUR11m). The business finished 2016 with a strong cash position of EUR3m (EUR1.75m 30 June 2016). The strong momentum enjoyed by the business in 2016 has continued into 2017 todate, with new business contracts signed to the value EUR5.7m in the first two months of the year.
Enquiries:
Venn Life Sciences Holdings Plc Tony Richardson, Chief Executive Tel: +353 154 99 Officer 341 Davy (Nominated Adviser, ESM Adviser and Joint Broker) Fergal Meegan / Matthew de Vere Tel: +353 1 679 White (Corporate Finance) 6363 Hybridan LLP (Co-Broker) Claire Louise Noyce Tel: +44(0) 20 3764 2341 Walbrook PR Ltd Tel: +44 (0) 20 7933 8787 or venn@walbrookpr.com Paul McManus Mob: +44(0) 7980 541 893 Lianne Cawthorne Mob: +44(0) 7584 391 303
About Venn Life Sciences:
Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation - Venn specialises in rapid deployment and management of multisite projects.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TSTSSWFWEFWSEID
(END) Dow Jones Newswires
March 03, 2017 02:00 ET (07:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions